Latest Profitability News

Page 185 of 426
Staude Capital Global Value Fund Limited (GVF) reported a robust FY2025 with a 15.8% rise in adjusted pre-tax NTA and a fully franked dividend of 3.3 cents per share, underpinned by its discount capture strategy.
Claire Turing
Claire Turing
29 Aug 2025
Staude Capital Global Value Fund Limited reported a 21% increase in net profit after tax for FY2025, driven by strong portfolio returns and a successful discount capture strategy. The company also declared a fully franked final dividend of 3.3 cents per share and completed a $16.9 million wholesale placement.
Victor Sage
Victor Sage
29 Aug 2025
MedAdvisor reported a 36% revenue drop in FY25, driven by US health program setbacks, and sold its ANZ business to focus on restructuring its US operations.
Ada Torres
Ada Torres
29 Aug 2025
Bathurst Resources reports a dip in FY25 earnings due to lower coal prices and operational challenges but pushes forward with key development projects Buller and Tenas, targeting production growth from FY29.
Maxwell Dee
Maxwell Dee
29 Aug 2025
MedAdvisor Limited reported a staggering $60.2 million loss for FY25, driven by operational challenges and asset impairments, while divesting its ANZ business and becoming debt-free.
Ada Torres
Ada Torres
29 Aug 2025
Jayride Group Limited revealed a 55.5% plunge in revenue to $2.42 million for the fiscal year ending June 2025, alongside a reduced net loss of $5.7 million, signaling some financial stabilization despite ongoing challenges.
Sophie Babbage
Sophie Babbage
29 Aug 2025
4DMedical Limited reported a 56% jump in FY2025 operating revenue driven by SaaS growth, while narrowing its net loss to $30.1 million. The company also secured $13.9 million in capital and a $10 million funding facility to accelerate product commercialisation.
Ada Torres
Ada Torres
29 Aug 2025
Bubs Australia Limited reports a striking turnaround in FY25 with revenue up 29% to $102.5 million and net profit soaring 124% to $5.17 million, driven by strong US and China growth. The company awaits permanent FDA approval, a pivotal factor for its future trajectory.
Victor Sage
Victor Sage
29 Aug 2025
Immuron Ltd reported a robust 49% increase in FY25 global sales, driven by strong Travelan® growth, while gearing up for a ProIBS launch and pivotal FDA meetings in 2025-26.
Ada Torres
Ada Torres
29 Aug 2025
Gale Pacific’s FY25 results reveal resilience amid US market challenges, with growth in Australia and the Middle East offsetting tariff impacts and prompting a major US operating restructure.
Victor Sage
Victor Sage
29 Aug 2025
GALE Pacific reported a slight revenue dip and a net loss in FY25, driven by US market challenges including tariffs and weak consumer demand. The company is now overhauling its US operations and diversifying manufacturing to restore profitability.
Victor Sage
Victor Sage
29 Aug 2025
Immuron Limited reported a strong 48.6% revenue increase driven by Travelan sales in Australia and North America, yet still recorded a $5.25 million net loss for FY25. The company’s cash reserves fell sharply, prompting a post-year capital raise.
Ada Torres
Ada Torres
29 Aug 2025